KAS
TVRD

Kestra Advisory Services’s Tvardi Therapeutics TVRD Stock Holding History

Kestra Advisory Services’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-308
Closed -$241K – 2040
2021
Q1 		$241K Sell
308
-76
-20% -$52K ﹤0.01% 1604
2020
Q4 		$213K Buy
384
+58
+18% +$30.4K ﹤0.01% 1678
2020
Q3 		$149K Buy
+326
New +$189K ﹤0.01% 1334

Other funds holding TVRD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Kestra Advisory Services's TVRD Position: Q2 2021 in Review

Kestra Advisory Services sold out of Tvardi Therapeutics (TVRD) in Q2 2021, closing a stake of 308 shares — an estimated $241K sold.

Kestra Advisory Services first reported a position in TVRD in Q3 2020 and held it in 3 quarters. The position peaked at $241K in Q1 2021. 173 funds tracked by Wall St. Rank hold TVRD as of Q2 2021.

  • Kestra Advisory Services reported no remaining Tvardi Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Kestra Advisory Services sold 308 Tvardi Therapeutics shares in Q2 2021, an estimated $241K.
  • Kestra Advisory Services first reported a position in Tvardi Therapeutics in Q3 2020 and held it in 3 quarters.
  • Kestra Advisory Services's Tvardi Therapeutics position peaked at $241K in Q1 2021.
  • 173 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2021.

Based on Kestra Advisory Services's 13F filing for Q2 2021, filed 28 Jul 2021.